Media Doctor Canada
Follow us on Twitter








"Novel drug may extend survival in pancreatic cancer"

Medical Post

Source: Medical Post

Published: 14 Oct 2021

Category: Pharmaceutical

Rating: (4 stars)

what they said (Hover the mouse cursor over underlined words for more info)

In advanced pancreatic cancer patients, a novel anti-neovascular therapy added to standard gemcitabine therapy substantially extended survival time compared with gemcitabine alone in a study presented at the European Society for Medical Oncology Congress.

The novel agent is cationic lipid complexed paclitaxel noparticles (EndoTAG-1), which targets activated negatively charged endothelial cells of tumour blood vessels...

The original article can be found at:

how did it rate? (more information)

Criteria Rating
Total Score 6 of 8
Availability of Treatment Not Applicable
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Satisfactory (?)
Costs of Treatment Not Applicable
Evidence Satisfactory (?)
Quantification of Benefits of Treatment Satisfactory (?)
Harms of Treatment Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

Regardless of some troubling aspects, this report successfully emphasized the preliminary nature of the treatment of pancreatic cancer with EndoTAG-1. Due to the fact that this treatment option is in its early stages the cost and availability information are assumed to be unavailable and thus, the story received a rating of "not applicable."

That being said, very little information was provided regarding the sources of information and potential conflicts of interest. The report contents were said to have been presented at a major conference and the report includes interviews with individuals from different academic research organizations. Even with this information, readers are not informed about whether the research was funded by the government or industry, or by an academic body.

The reports does state that "the treatment [with EndoTAG-1] was well-tolerated, with the main side-effects being fever and chills." However, there is no indication as to how often these adverse reactions were seen in the target population.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada